Sarepta Therapeutics

SRPT63

$122.19arrow_drop_down0.93%-$1.15

SRPT63

$122.19

arrow_drop_down0.93%-$1.15

Performance History

Key Stats
Open	$123.30
Prev. Close	$123.29
EPS	0.75
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	120.95	124.48
52 Week Range	55.25	173.25

Ratios







EPS	0.75

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Inc (SRPT) is a biopharmaceutical company focused on the discovery and development of innovative RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The company is known for its groundbreaking work in the field of Duchenne muscular dystrophy (DMD), a devastating genetic disorder that primarily affects boys. Sarepta's mission is to improve the lives of DMD patients and their families by delivering transformative therapies that address the underlying causes of the disease.

Sarepta's flagship product is Exondys 51, the first and only FDA-approved treatment for DMD patients with a specific genetic mutation. Exondys 51 is designed to enable the production of a functional dystrophin protein, which is essential for muscle function. The drug has shown promising results in clinical trials, with patients experiencing significant improvements in muscle strength and function.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Headquarters: Cambridge
Employees: 1162
Exchange: NASDAQ

Keep an eye on Sarepta Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Sarepta Therapeutics 's (SRPT) price per share?

The current price per share for Sarepta Therapeutics (SRPT) is $122.2. The stock has seen a price change of -$1.15 recently, indicating a -0.94% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Sarepta Therapeutics (SRPT)?

For Sarepta Therapeutics (SRPT), the 52-week high is $173.25, which is 41.78% from the current price. The 52-week low is $55.25, the current price is 121.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Sarepta Therapeutics (SRPT) a growth stock?

Sarepta Therapeutics (SRPT) has shown an average price growth of -1.33% over the past three years. It has received a score of 74 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sarepta Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Sarepta Therapeutics (SRPT) stock price performance year to date (YTD)?

As of the latest data, Sarepta Therapeutics (SRPT) has a year-to-date price change of 27.01%. Over the past month, the stock has experienced a price change of 1.49%. Over the last three months, the change has been -13.12%. Over the past six months, the figure is -9.51%. Looking at a longer horizon, the five-year price change stands at 34.56%.

help

Is Sarepta Therapeutics (SRPT) a profitable company?

Sarepta Therapeutics (SRPT) has a net income of -$535.98M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.91% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -0.19% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.24B, with a revenue growth rate of 33.26%, providing insight into the company's sales performance and growth. The gross profit is $1.09B. Operating income is noted at -$267.82M. Furthermore, the EBITDA is $163.55M.

help

What is the market capitalization of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics (SRPT) has a market capitalization of $11.74B. The average daily trading volume is 122.02, indicating the stock's liquidity and investor engagement.

News

MRNA

CANCER VACCINES

THERAPEUTICS

PERSONALIZED MEDICINE

MULTIVALENT VACCINES

Oct 14, 2024

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

WAVE LIFE SCIENCES

SAREPTA THERAPEUTICS

DUCHENNE MUSCULAR DYSTROPHY

BIOTECH STOCKS

Oct 3, 2024

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

BIOTECH

WEIGHT LOSS

RARE DISEASES

DUCHENNE MUSCULAR DYSTROPHY

Sep 13, 2024

These 2 Biotech Stocks Are Set to Soar

GENE THERAPY

MARKET GROWTH

GENETIC DISORDERS

PERSONALIZED MEDICINE

Sep 12, 2024

Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology

Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today - Sarepta Therapeutics ... - Benzinga